tirzepatide europe Eli Lilly gets nod to launch weight-loss drug in Hong Kong - Bloomberg News EU drug regulator to review

Per a March 3, 2026 FDA press announcement (FDA.gov press announcement, March 3, 2026), the FDA issued warning letters to 30 telehealth companies for making false or misleading claims about compounded GLP-1 products, including claims that implied sameness with FDA-approved medications

Semaglutide base is the active ingredient used in FDA-approved products

Use Telehealth for Personalized Advice Consulting a healthcare professional is crucial when side effects become bothersome or severe

Compounded semaglutide and compounded tirzepatide are not FDA approved or evaluated by the FDA for safety, effectiveness or quality

Congrats FJ